A detailed history of Sivia Capital Partners, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Sivia Capital Partners, LLC holds 14,213 shares of EXEL stock, worth $591,971. This represents 0.17% of its overall portfolio holdings.

Number of Shares
14,213
Previous 14,362 1.04%
Holding current value
$591,971
Previous $633 Million 7.27%
% of portfolio
0.17%
Previous 0.22%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 20, 2025

SELL
$36.22 - $46.25 $5,396 - $6,891
-149 Reduced 1.04%
14,213 $587 Million
Q2 2025

Jul 09, 2025

BUY
$34.13 - $46.26 $94,335 - $127,862
2,764 Added 23.83%
14,362 $633 Million
Q1 2025

Apr 11, 2025

BUY
$32.38 - $39.16 $70,005 - $84,663
2,162 Added 22.91%
11,598 $428 Million
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $181,643 - $227,690
9,436 New
9,436 $226 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Sivia Capital Partners, LLC Portfolio

Follow Sivia Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sivia Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sivia Capital Partners, LLC with notifications on news.